Abstract
Introduction
The link between smoking and increased morbidity and mortality have been long established, and current trends indicate that there are one billion smokers worldwide and 500 million will die prematurely from smoking-related diseases. 1 Smoking has been shown to have harmful effects on numerous organs of the body and the list of diseases where smoking has been recognized as contributory factor is extensive. 2 It has long been accepted that cigarette smoking is a classical and major risk factor in the development of cardiovascular disease (CVD) and atherosclerosis. 3, 4 More recently, it has been recognized that CVD contains a component of inflammation and has even been referred to as an inflammatory disease. 5, 6 In addition, a link has been Cigarette smoking, a risk factor for chronic subclinical inflammation and a predictor of metabolic syndrome in adult healthy population of Bangladesh established between several other chronic inflammatory diseases and smoking, including chronic obstructive pulmonary disease (COPD) 7 , rheumatoid arthritis, systemic lupus erythematosus 8 and Crohn's disease. 9 Although the mechanisms linking smoking to these diseases are not well understood, interest in finding relationship between inflammatory markers and smoking has been gathering pace to provide explanations for smoking-mediated morbidity and mortality. One such inflammatory marker, is C-reactive protein (CRP), which may be easily and sensitively measured in a variety of clinical situations to monitor disease progression.
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C-reactive protein (CRP) is an inflammatory marker whose expression is markedly up regulated during inflammation. 11 It is the acute phase protein synthesized in the liver and regulated to a large extent by pro inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). 12,13 Furthermore, new, highly sensitive assays for CRP (Hs-CRP assays) measure levels within the "normal" range i.e., low grade inflammation or subclinical inflammation thus enabling careful evaluation of underlying systemic inflammation in apparently healthy people as well as those with established cardiac and metabolic diseases. Moreover, Hs-CRP assay is the inflammatory marker with improved precision, standardization and other characteristics. Recent prospective studies have demonstrated that subjects with low grade inflammation have a higher risk of cardiovascular diseases. 14, 15, 16 Evidence suggests that elevation of CRP reflect not only local inflammation at atherosclerotic lesions but also systemic abnormalities related to insulin resistance, such as increase in fasting insulin, body mass index (BMI), systolic blood pressure and triglyceride (TG) as well as decrease in high density lipoprotein cholesterol (HDL-c). 17, 18, 19 Unhealthy lifestyle might increase the risk of CVDs. 20, 21, 22 These habits include physical inactivity, calorie dense diets, alcohol drinking, smoking and psychosocial stress. Previous studies have demonstrated the adverse effect of smoking on CVDs, e.g. tobacco use increases triglycerides (TG) and decreases HDL-c levels. It has also been shown that total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), and Total Cholesterol/HDL-c ratio are strongly related to smoking. 23 There are significant improvements in LDL-c, HDL-c and the HDL-c to LDL-c ratio 8 weeks after cutting down on smoking. 23 Globally, tobacco use accounts for about 10% of all CVD related mortality, with the highest occurrences being in low to mid-income countries.
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Yet awareness about the cardiovascular implications of cigarette smoking is still unacceptably low considering that smoking is a completely preventable cause of CVD. Previous studies have demonstrated the adverse effect of smoking on serum lipid profile. 20, 21, 22, 23 We set out to examine lifestyle factors such as smoking, and levels of CRP, Focusing on the use of CRP measurement to predict long-term outcome in smokers.
Subjects and Methods
An invitation was made to the volunteers of the study through personal contact to report in the department of Biochemistry and Physiology, BIRDEM in fasting condition. Subjects reported were examined for their wellbeing. Purpose and nature of the study were
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explained to them. Consented respondents were given appointment for blood sampling. Detailed medical and personal history was recorded on the day of blood sampling in a pre-designed case record form.
Anthropometric measurements and blood pressure recording
Volunteer's height (in meter) and weight (kg), waist and hip (cm) circumference were taken following standard procedure. Cut-off values for BMI (normal 22.9 Kg/m2; over weight 23-27.5 and obese 27.5) and WHR (male-0.90 and female-0.80) were used as per WHO, 2004 guidelines for Asian population. Blood pressure (average of two independent measurements) was recorded using barometric Sphygmomanometer.
Five milliliter of venous blood was drawn from each subject by vein puncture at fasting and drawn blood was allowed to clot. After 20 minutes samples were centrifuged at 3000 rpm for 10 minutes. Separated serum was aliquoted in micro centrifuge tubes, labeled and preserved at (-30°C) for biochemical analyses.
Biochemical methods
Glucose was measured by (glucose-oxidase) and Total Cholesterol, Triglyceride and HDL-c were measured (by enzymatic colorimetric) method using in the Biochemistry Auto-analyzer 'Hitachi 704' reagents of RANDOX Laboratories Ltd., UK. LDL-c was calculated using Fried wald formula. The method was not applied when triglyceride level exceeded 400 mg/dL. Serum Hs-CRP was estimated by enzyme linked immunosorbant assay (ELISA) method.
Statistical methods
Data were expressed as mean ± SD and number (percent). Statistical analyses were performed using Statistical Package for Social Science (SPSS) for Windows Version 17. Two tailed P value <0.05 was taken as significant level.
Recruitment criteria
A total number of 149 volunteers aged 30-60 yrs were finally recruited in this study. Subjects suffered from acute illness in the last three months, subjects with secondary obesity, pregnancy, known primary hyperlipidemias, hereditary or systemic inflammatory diseases, on any regular medications or significant physical training program were excluded.
Ethical Consideration
The Helsinki Declaration on medical ethics was respected in the surveys. The protocol was approved by the Ethical Committee of Diabetic Association of Bangladesh.
Results
Of the total subjects 73 (48.9%) were nonsmoker and 76 (51%) were smokers. Cigarette smoking, a risk factor for chronic subclinical inflammation and a predictor of metabolic syndrome in adult healthy population of Bangladesh (Table II) . 
Discussion
Low grade inflammation may be part of the 'common soil' underlying the metabolic syndrome, Type 2 Diabetes Mellitus and cardiovascular diseases. CRP is a nonspecific marker widely used to monitor treatment of cardiovascular diseases (high serum CRP levels indicate poor outcome of heart disease). A healthy lifestyle decreases serum CRP levels, while obesity, physical inactivity, and smoking increase them. 20, 21, 22 Our findings support the hypothesis that lifestyle factors such as smoking adversely affect inflammatory and metabolic processes. Our results showed an association between smoking and elevated Fasting Serum Glucose, Triglyceride, Hs-CRP as well as low HDL-c. The Hs-CRP concentration found to be elevated by smoking 17, 25 which can be explained by three Cigarette smoking, a risk factor for chronic subclinical inflammation and a predictor of metabolic syndrome in adult healthy population of Bangladesh such as, Growth hormone, Cortisol, Glucagon and Catecholamines, all of which raise blood glucose level. 32 A case control study based on this showed that smokers had higher levels of Hs-CRP, FPG and TG but lower levels of HDL-c than nonsmokers. 17 Smoking had a dyslipidaemic effect and can increase Total Cholesterol, LDL-c and Trigliceride; furthermore, it can decrease serum HDL-c level. 17 In agreement with Oh et al, 33 we find that chronic smoking is associated with higher Triglycerides and lower HDL-c.
In our study, BMI, body fat and WHR in smokers were lower than in non-smokers. Some other studies have demonstrated lower BMI in current smokers. Numerous cross-sectional studies indicate that body weight, or body mass index (BMI; in kg/m2), is lower in cigarette smokers than in nonsmokers. [34] [35] [36] [37] In the World Health Organization Monitoring Cardiac Disease (WHO MONICA) surveys, BMI was lower in smokers than in smokers, and there was no population in which smokers had a higher BMI than did nonsmokers. 38 In the second National Health and Nutrition Examination Survey (NHANES II) study (1976 -1980) , smokers weighed less than nonsmokers, and body leanness increased with the duration (but not with the intensity) of smoking. 39 The effect of smoking on body weight could lead to weight loss by increasing the metabolic rate, decreasing metabolic efficiency, or decreasing caloric absorption (reduction in appetite), all of which are associated with tobacco use. The metabolic effect of smoking could explain the lower body weight found in smokers. Smoking a single cigarette has been shown to induce a 3% rise in Energy Expenditure within 30 min. 40 And could reduce appetite, which likely explains why smokers tend to have lower body weight than do nonsmokers.
Conclusion
Elevated Hs-CRP has been closely linked with the development of atherosclerosis and is associated with the development of and mortality from CVD. Though not proven here, our study suggests that aggravation of systemic inflammation by cigarette smoking may account for the increased risk of CVD in smokers. Finally, we can conclude that subclinical atherosclerosis is independently accelerated via continuous smoking and that the smoking-induced promotion of atherosclerotic change is closely associated with inflammatory reactions.
